INVESTORS

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Achillion Reports Second Quarter 2016 Financial Results
NEW HAVEN, Conn. , Aug. 04, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today reported financial results for the three and six months ended June 30, 2016. For the second quarter of 2016, Achillion reported a net loss of $18.5 million or $0.14 per share, compared with a
View HTML
Toggle Summary Achillion to Present at the 2016 Wedbush PacGrow Healthcare Conference
NEW HAVEN, Conn., Aug. 09, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion, will present a corporate overview at the 2016 Wedbush PacGrow Healthcare Conference on Tuesday, August
View HTML
Toggle Summary Achillion Announces Upcoming Presentation of Interim Phase 2a Results From the Janssen Sponsored Trial of Odalasvir, AL-335 and Simeprevir at the European Association for the Study of the Liver (EASL) Special Conference
ePoster presentation to detail study results including SVR12 for eight and six week triplet regimen and eight week doublet regimen
View HTML
Toggle Summary Achillion to Present at Two Upcoming Investor Conferences
NEW HAVEN, Conn., Sept. 01, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion, will present a corporate overview at two upcoming investor conferences: Baird 2016 Healthcare
View HTML
Toggle Summary Achillion Presents Novel Research on Factor D Inhibition at the XXVIth International Complement Workshop
NEW HAVEN, Conn., Sept. 06, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced the presentation of two posters which detailed novel preclinical research into complement biology and the inhibition of factor D by ACH-4471 during the XXVI th International Complement
View HTML
Toggle Summary Achillion Announces 100% SVR Reported in Janssen's Phase 2a Trial Evaluating Triple Combination of Odalasvir, AL-335, and Simeprevir for Genotype 1 Treatment-Naive HCV
- New data released today in abstract for upcoming EASL / AASLD Special Conference: New Perspectives in Hepatitis C Virus Infection — The Roadmap For Cure - - Janssen advancing triple combination into Phase 2b clinical trial - NEW HAVEN, Conn., Sept. 09, 2016 (GLOBE NEWSWIRE) -- Achillion
View HTML
Toggle Summary Achillion Announces 100% SVR12 in the 6-Week and 8-Week Cohorts in Janssen's Phase 2 Trial Evaluating the Triple Combination Treatment Regimen Including Odalasvir, AL-335, and Simeprevir for Genotype 1 Treatment-Naïve HCV
- ePoster presented today at the EASL / AASLD Special Conference: New Perspectives in Hepatitis C Virus Infection — The Roadmap For Cure - - Ongoing Phase 2 development focusing on triple combination for treatment durations as short as six weeks for broad HCV population — PARIS, Sept.
View HTML
Toggle Summary Achillion to Present at the Credit Suisse 25th Annual Healthcare Conference
NEW HAVEN, Conn., Nov. 02, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion, will present a corporate overview at the 25 th Annual Credit Suisse Healthcare Conference on Monday,
View HTML
Toggle Summary Achillion Reports Third Quarter 2016 Financial Results And Provides Update On Clinical Programs
Janssen HCV triple combination candidate JNJ-4178 reported 100% SVR12 after 6 weeks of therapy; global phase IIB study to begin 4Q 2016 Achillion's phase I MAD study with oral factor D inhibitor ACH-4471 ongoing; strong complement inhibition observed in in vivo and ex vivo assays Company advancing
View HTML
Toggle Summary Achillion Announces Upcoming Presentations of Novel Research Into Complement Biology at the 58th Annual Meeting of the American Society of Hematology
NEW HAVEN, Conn., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc.  (Nasdaq:ACHN) today announced that two abstracts have been accepted for poster presentation at the 58th Annual Meeting of the American Society of Hematology (ASH) in San Diego, CA, December 3 - 6, 2016.  "The data
View HTML